Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
BACKGROUND
The oral multikinase inhibitor sorafenib is the new reference standard for the treatment of advanced hepatocellular carcinoma. Only few data are available on the use of sorafenib in cholangiocellular carcinoma (CCC).


METHODS
A 70-year-old male patient with histologically confirmed unresectable intrahepatic cholangiocellular carcinoma not amenable to any other systemic chemotherapy was treated with sorafenib 400 mg bid.


RESULTS
Sorafenib treatment led to a significant improvement of tumor symptoms, liver function parameters, and a decrease in tumor marker levels. The best radiologic tumor response according to RECIST and mRECIST was stable disease (SD) with a time to progression (TTP) of 5.7 months. Side effects of sorafenib (diarrhea, fatigue, and skin toxicity) were low-grade and manageable. Twenty-four months after sorafenib initiation the patient is still alive and presents in a well-preserved physical constitution, performance status 0. Gene analyses revealed that neither B-raf nor K-ras was mutated in our patient.


CONCLUSIONS
Sorafenib was effective and well-tolerated in a patient with advanced cholangiocellular carcinoma. Prospective trials are warranted to evaluate the benefit of sorafenib in unresectable CCC.
Department of Gastroenterology & Hepatology, AKH & Medical University of Vienna, Vienna, Austria.
Matthias
M
Pinter
Wolfgang
W
Sieghart
Michael
M
Reisegger
Friedrich
F
Wrba
Markus
M
Peck-Radosavljevic
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use*; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib
Oncology. 2004;66(3):167-79
15218306
Cancer. 1995 Jan 1;75(1 Suppl):171-90
8000995
Wien Klin Wochenschr. 2008;120(9-10):280-3
18545951
Wien Klin Wochenschr. 2010 Jan;122(1-2):45-9
20177859
J Clin Gastroenterol. 2007 Nov-Dec;41(10):911-7
18090160
Am J Surg. 1993 Dec;166(6):768-71; discussion 771-2
8273866
J Gastrointest Cancer. 2007;38(2-4):154-6
19089671
Biochem Pharmacol. 2007 May 1;73(9):1308-17
17266941
Br J Cancer. 2007 Mar 26;96(6):896-902
17325704
Ann Surg Oncol. 2008 Feb;15(2):600-8
17987347
Br J Cancer. 2010 Jan 5;102(1):68-72
19935794
N Engl J Med. 2010 Apr 8;362(14):1273-81
20375404
Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20
14762851
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Semin Liver Dis. 2010 Feb;30(1):52-60
20175033
Gut. 2003 May;52(5):706-12
12692057
Clin Cancer Res. 2009 Jul 15;15(14):4554-60
19584155
Oncologist. 2009 Jan;14(1):70-6
19144684
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9
11573044
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206